cis-hinokiresinol, a norlignan from Anemarrhena asphodeloides, inhibits angiogenic response in vitro and in vivo.
cis-Hinokiresinol (CHR) is a norlignan constituent from Anemarrhena asphodeloides BUNGE (Liliaceae), which shows hyaluronidase inhibitory activity. In the present studies, we have demonstrated that CHR selectively inhibited endothelial cell proliferation compared with cancer cells, and especially basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation. Furthermore, endothelial cell migration and tube formation, two important steps in the angiogenic process, were also inhibited by CHR. Moreover, CHR reduced the vessel growth induced by VEGF in the mouse corneal neovascularization model. These results suggest that CHR may prove useful for the development of a novel angiogenesis inhibitor.
Jeong
Sei-Joon
SJ
Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Higuchi
Ryuichi
R
Ono
Mayumi
M
Kuwano
Michihiko
M
Kim
Youn-Chul
YC
Miyamoto
Tomofumi
T
D031403:Anemarrhena / Q000737:chemistry*; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000302:isolation & purification / Q000493:pharmacokinetics; D000818:Animals; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects; D003315:Cornea / Q000098:blood supply / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000187:drug effects / Q000502:physiology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors / Q000494:pharmacology; D006821:Hyaluronoglucosaminidase / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D017705:Lignans / Q000009:adverse effects / Q000737:chemistry* / Q000302:isolation & purification / Q000493:pharmacokinetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D010598:Pharmacognosy / Q000379:methods; D010636:Phenols / Q000009:adverse effects / Q000302:isolation & purification / Q000493:pharmacokinetics*; D027343:Rhizome / Q000737:chemistry; D013237:Stereoisomerism; D014407:Tumor Cells, Cultured; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D017705:Lignans; D010636:Phenols; D016222:Fibroblast Growth Factor 2; C119821:hinokiresinol; D006821:Hyaluronoglucosaminidase